Seer Inc - SEER STOCK NEWS

Seer, Inc. reported financial results for Q4 and full year 2023, achieving $4.4 million revenue in Q4, a 4% decrease from 2022, and $16.7 million for the full year, an 8% increase. They shipped 23 instruments in 2023, expanded internationally, and had their first customer publication in Nature Communications. The company ended the year with $373 million in cash and investments. Despite a decrease in revenue for Q4, Seer expects 2024 revenue to be in the range of $18-20 million, a growth of 14% over 2023.

Seer, Inc. (SEER) will be participating in the TD Cowen 44th Annual Health Care Conference in Boston, MA. Seer's management will engage in a fireside chat and Q&A session on March 4th. A live webcast and archived replay will be accessible on Seer's investor website.

Seer, Inc. (NASDAQ: SEER) announced a study led by Weill Cornell Medicine demonstrating the identification of protein-altering variants for population-scale protein quantitative trait loci (pQTL) studies using Seer's Proteograph workflow. The study, published in Nature Communications, quantified over 18,000 peptides from approximately 3,000 proteins in more than 320 blood samples, detecting and quantifying blood-circulating proteins in the presence of protein-altering variants. The research revealed 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV. Some MS-PAVs were aligned with known genetic markers (cis-pQTLs), and some overlapped with trans-pQTLs, shedding light on potential causal proteins. The study also identified proteins overlooked by traditional methods, such as the incretin pro-peptide (GIP) linked to type 2 diabetes and cardiovascular disease. Seer's recently launched Proteograph XT Assay Kit for the Proteograph Product Suite allows for unbiased proteomics research at unprecedented speed, more than doubling throughput while maintaining high-resolution insights. Seer's approach provides unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine.

Seer, Inc. (Nasdaq: SEER) will report financial results for Q4 and full year 2023 on February 29, 2024. A conference call will be webcasted by company management at 1:30 p.m. PT / 4:30 p.m. ET. Live audio can be accessed on Seer’s Investor section at investor.seer.bio.

Seer, Inc. (Nasdaq: SEER) to participate in J.P. Morgan 42nd Annual Health Care Conference, presenting disruptive proteomics platform

Seer, Inc. (Nasdaq: SEER) to present at Canaccord MedTech, Diagnostics and Digital Health and Services Forum. Seer's management will present on November 16th at 1:00 p.m. Eastern Time. A live webcast will be available on the Investor section of Seer’s website at investor.seer.bio.

Seer, Inc. (NASDAQ: SEER) has been recognized as the 'Proteomics Solution of the Year' in the 2023 BioTech Breakthrough Awards program and named to the 2023 Deloitte Technology Fast 500. The company's Proteograph XT Assay Kit has contributed to its momentum in opening up a new gateway to the proteome. Seer's CEO, Omid Farokhzad, expressed excitement about the accolades, highlighting the company's dedication to innovation, collaboration, and advancing human health.

Seer, Inc. (Nasdaq: SEER) reports 5% revenue increase to $4.2 million in Q3 2023. Expanded geographically with new partners and added Panome Bio to Centers of Excellence program. Achieved ISO 27001 and ISO 13485 certifications. Ended quarter with $380.8 million in cash, cash equivalents, and investments.

Panome Bio has joined Seer Inc.'s COE Program, adding deep, unbiased proteomics to their metabolomics platform. Panome Bio provides biopharma innovators with access to biomolecules using its proprietary Next Generation Metabolomics™ technology. Seer's COE network aims to accelerate the adoption of deep, unbiased proteomics.